Jon Snodgres Sells 2,000 Shares of Repligen Co. (NASDAQ:RGEN) Stock

Repligen Co. (NASDAQ:RGENGet Rating) CFO Jon Snodgres sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $220.00, for a total transaction of $440,000.00. Following the completion of the transaction, the chief financial officer now owns 37,187 shares of the company’s stock, valued at approximately $8,181,140. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Repligen Price Performance

Shares of RGEN opened at $240.40 on Thursday. The firm has a market capitalization of $13.08 billion, a PE ratio of 95.02 and a beta of 1.07. The company’s 50-day moving average is $171.99 and its 200-day moving average is $173.32. Repligen Co. has a fifty-two week low of $137.21 and a fifty-two week high of $327.32.

Repligen (NASDAQ:RGENGet Rating) last issued its quarterly earnings data on Tuesday, August 2nd. The biotechnology company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.19. Repligen had a net margin of 19.86% and a return on equity of 11.13%. The company had revenue of $207.63 million for the quarter, compared to analyst estimates of $189.06 million. During the same period in the prior year, the firm earned $0.79 earnings per share. The company’s revenue was up 27.4% on a year-over-year basis. Analysts predict that Repligen Co. will post 3.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Repligen

A number of hedge funds have recently bought and sold shares of RGEN. Millennium Management LLC increased its position in Repligen by 186.2% during the fourth quarter. Millennium Management LLC now owns 309,482 shares of the biotechnology company’s stock worth $81,963,000 after acquiring an additional 201,342 shares during the period. Impax Asset Management Group plc increased its position in Repligen by 31.6% during the fourth quarter. Impax Asset Management Group plc now owns 813,012 shares of the biotechnology company’s stock worth $214,295,000 after acquiring an additional 195,300 shares during the period. Conestoga Capital Advisors LLC increased its position in Repligen by 18.2% during the first quarter. Conestoga Capital Advisors LLC now owns 772,719 shares of the biotechnology company’s stock worth $145,341,000 after acquiring an additional 118,818 shares during the period. Echo Street Capital Management LLC increased its position in Repligen by 23.7% during the first quarter. Echo Street Capital Management LLC now owns 562,249 shares of the biotechnology company’s stock worth $105,753,000 after acquiring an additional 107,884 shares during the period. Finally, Natixis Advisors L.P. increased its position in Repligen by 82.3% during the first quarter. Natixis Advisors L.P. now owns 201,707 shares of the biotechnology company’s stock worth $37,939,000 after acquiring an additional 91,047 shares during the period. 86.82% of the stock is owned by institutional investors.

Analysts Set New Price Targets

RGEN has been the subject of several research analyst reports. SVB Leerink reiterated a “maintains” rating on shares of Repligen in a report on Wednesday. Craig Hallum reduced their target price on shares of Repligen from $286.00 to $274.00 in a report on Thursday, April 28th. Stephens upped their price target on shares of Repligen from $220.00 to $275.00 and gave the stock an “overweight” rating in a research report on Wednesday. UBS Group began coverage on shares of Repligen in a research report on Wednesday, July 20th. They set a “buy” rating and a $213.00 price target on the stock. Finally, KeyCorp upped their price target on shares of Repligen from $245.00 to $260.00 and gave the stock an “overweight” rating in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $276.00.

Repligen Company Profile

(Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Further Reading

Insider Buying and Selling by Quarter for Repligen (NASDAQ:RGEN)

Want More Great Investing Ideas?

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.